Ascentage Pharma Group International vs Ligand Pharmaceuticals
AAPG and LGND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AAPG and LGND compare
Ligand Pharmaceuticals grew revenue faster over the last twelve months (1.0% versus −41.5% for Ascentage Pharma Group International).
Ligand Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with −216% at Ascentage Pharma Group International.
Ligand Pharmaceuticals scores higher on the StockData Score (6 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AAPG | LGND |
|---|---|---|
| Size and price | ||
| Market cap | – | $5.9B |
| Share price | $13.14 | $293.81 |
| Change, 1 year | −61.7% | 46.3% |
| Change, 5 years | – | 87.3% |
| Beta (5Y) | 1.43 | 0.84 |
| Employees | 767 | 47 |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 | 3 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 128× |
| P/S | – | 23.2× |
| P/B | – | 6.1× |
| EV/EBITDA | – | 108× |
| P/FCF | – | 64.8× |
| FCF yield | – | 1.5% |
| Fair value | – | $55.15 |
| Margin of safety | – | −433% |
| Growth | ||
| Revenue growth (TTM) | −41.5% | 1.0% (better) |
| Revenue growth, 5Y average | – | 10.4% |
| Net income growth (TTM) | – | 5.9% |
| EPS growth (TTM) | – | 18.7% |
| Profitability | ||
| Gross margin | 91.5% | – |
| Operating margin | – | 10.1% |
| Net margin | −216% | 20.3% (better) |
| FCF margin | −209% | 35.7% (better) |
| Return on equity | −156% | 5.4% (better) |
| Return on invested capital | – | 2.6% |
| Financial health | ||
| Debt / equity | 1.50 | 1.17 (better) |
| Net debt / EBITDA | – | 11.26 |
| Interest coverage | – | 3.1× |
| Current ratio | 1.79 (better) | 1.22 |
| Altman Z-score | – | 3.32 |
| Piotroski F-score | – | 6 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.00% | 113% |
| Held by insiders | 13.0% | 2.6% |
| Insider net buying, 12 months | – | −$36.5M |
Go deeper
- AAPG stock overview
- AAPG income statement
- AAPG valuation and score
- LGND stock overview
- LGND income statement
- LGND valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.